Crinetics Pharmaceuticals, Inc. 8-K

What Happened Crinetics Pharmaceuticals, Inc. (CRNX) filed a Form 8-K (Item 5.02) reporting that Jeff Knight notified the company on March 17, 2026 that he will resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The filing states Mr. Knight is leaving to pursue another opportunity and that his resignation is not due to any disagreement with the company’s operations, policies or practices.

Key Details

• Resignation notice given: March 17, 2026; effective on or about April 10, 2026.
• Officer departing: Jeff Knight, Chief Development and Operating Officer.
• Reason stated: To pursue another opportunity; not related to any disagreement with the Company.
• Management impact: Mr. Knight’s managerial responsibilities and direct reports will be reassigned to other members of the executive leadership team.
• Filing: Form 8-K signed by President & CEO R. Scott Struthers on March 23, 2026.

Why It Matters Executive departures can affect program oversight and operational continuity. For investors, the key facts are the timing of the change, that the company reports no disagreement, and that responsibilities will be reassigned internally. Monitor subsequent company disclosures for any interim or permanent appointment, changes to development timelines, or updates to leadership responsibilities that could affect execution of Crinetics’ clinical programs.